Vir Biotechnology, Inc. announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer. Dr. Calcagno will be responsible for leading the Companys business development efforts, optimizing existing alliances and establishing new strategic industry and public-private partnerships. He reports to Virs Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and joins Virs executive management team.

Dr. Calcagno joins Vir from Johnson &Johnson (J&J), where he spent more than 12 years holding leadership roles of increasing responsibility within all three divisions of J&J Innovation (JJI), including as Global Transactions Lead for Infectious Diseases &Vaccines and as Head of JLABS Bay Area. He was also instrumental in establishing JJIs Western North America Innovation Center. Prior to J&J, Dr. Calcagno served as a Principal and Kauffman Fellow at Scale Venture Partners; Chief Business Officer and Chief Financial Officer at a venture-backed therapeutics company; a research analyst at Hambrecht and a management consultant at McKinsey &Company.

Dr. Calcagno earned an A.B. in biology from Harvard University and an M.D. from Harvard Medical School, where he was a Rotary International Ambassadorial Scholar. He completed an internship, residency, chief residency and clinical pharmacology fellowship at the University of California, Los Angeles, and remains a licensed physician. Throughout his career, he has served on the boards of more than a dozen life sciences companies.